ReCode Therapeutics, a genetic medicines platform with targeted delivery and a pipeline of mRNA and gene correction therapeutics, announced that it has formed a scientific advisory board and added Scientific Adviser Elliott Sigal, M.D., Ph.D.
ReCode has offices in Dallas and Menlo Park, California.
Chaired by Daniel J. Siegwart, Ph.D., inaugural members of the board include Rafael Amado, M.D., Carrolee Barlow, M.D., Ph.D., Justin Hanes, Ph.D., and Eric Olson, Ph.D. These advisers will work closely with management to support ReCode’s expansion of its selective organ targeting (SORT) lipid nanoparticle (LNP) platform capabilities and advance its pipeline.
“We’re honored and privileged to bring together this esteemed group of medical and scientific advisors who will work with us to shape ReCode’s pipeline of genetic medicines,” Shehnaaz Suliman, M.D., MBA, M.Phil., CEO and a board member of ReCode Therapeutics.
“These thought leaders bring tremendous expertise in genetic medicine, delivery technology, and drug development,” Suliman added, “which will be invaluable as we expand our differentiated platform into new areas, including muscle, central nervous system, liver, and oncology indications, and advance our lead mRNA programs for primary ciliary dyskinesia and cystic fibrosis into the clinic in 2023.”
The founding members of ReCode’s SAB include:
- Board Chair Siegwart is the W. Ray Wallace Distinguished Chair in Molecular Oncology Research and associate professor in the Department of Biochemistry at the University of Texas Southwestern Medical Center, and a co-founder of ReCode Therapeutics.
- Amado serves as executive vice president of research and development at Allogene Therapeutics Inc. He most recently served as president of research and development at Adaptimmune Therapeutics PLC, after serving as its chief medical officer.
- Barlow most recently was the chief medical officer of Escape Bio, Inc. Prior to joining Escape Bio, she served as chief executive officer of the Parkinson’s Institute and Clinical Center. Barlow was also formerly acting chief medical officer at Amicus Therapeutics and was a co-founder, chief scientific officer, and chief medical officer of BrainCells Inc.
- Hanes is the Lewis J. Ort professor of ophthalmology at the Wilmer Eye Institute at Johns Hopkins University, with secondary appointments in chemical & biomolecular engineering, environmental health sciences, neurosurgery, and oncology. A globally recognized leader in research at the interface of nanotechnology and medicine, Hanes focuses his research on the delivery of genetic medicines, characterization of mucus and design, and testing of nanoparticles that can penetrate mucus barriers.
- Olson is the founding chair of the department of molecular biology at the University of Texas Southwestern Medical Center. He also directs the Hamon Center for Regenerative Science and Medicine and the Wellstone Center for Muscular Dystrophy Research.
New scientific adviser
Elliott Sigal, M.D., Ph.D., ReCode’s newest scientific adviser, serves as co-chair of the scientific advisory board for Amgen Inc. and as a senior advisor to New Enterprise Associates, Inc. He’s a member of the board of directors for Adaptimmune Therapeutics, Vir Biotechnology, Surface Oncology, Tessera Therapeutics, and Affinia Therapeutics.
In June, the biopharma startup closed a $120 million extension to a funding round it raised last year to help bring its lead programs to human trials and “follow the science” to target new diseases.
Go here for more DI People news.
You’ll find a roundup of innovators to know in North Texas. DI People includes hires, leadership moves, and accolades. Send us your news here.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
ReCode Therapeutics, a biopharmaceutical startup using a non-viral lipid nanoparticle delivery platform for gene therapies, has closed a $120 million extension to a funding round it raised last year to help bring its lead programs to human trials and “follow the science” to target new diseases. With a research team working out of BioLabs' life sciences facility at Pegasus Park, ReCode aims to grow its global team from about 70 to 100 over the next year.
-
In this week’s roundup of hires, promotions, and accolades in North Texas, you’ll also find news from Exela Technologies, Newmark, OrangeGrid, RailPros, Aimbridge Hospitality, Integrity Marketing Group, Smoothie King, Bank of Texas, MD7, Salvation Army, and more. Plus, you'll find board appointments including Texas Mutual Insurance, Zimperium, and the Ebby Halliday Foundation.
-
The TechFW board has named its 2022 leadership.
-
It's the first transition of chairs since the organization’s inception. The new chair was announced at the 2022 State of My Possibilities, a virtual event. Plus, Big Thought's Byron Sanders joined My Possibilities' Michael Thomas in a discussion of the importance of creativity and innovation in the charitable sector. Here's a takeaway.
-
In this week's roundup of hires, promotions, and accolades in North Texas, you'll also find news from VERTESS, Mr. Cooper, Active Cyber, EarthX, SWK Holdings, and more. Plus, Fort Worth Mayor Mattie Parker makes an appointment to the city council's Entrepreneurship and Innovation Committee.
